Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic …
R Noviyani, S Youngkong, S Nathisuwan… - BMJ Evidence-Based …, 2022 - ebm.bmj.com
Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …
Big data and real-world data based cost-effectiveness studies and decision-making models: a systematic review and analysis
Background: Big data and real-world data (RWD) have been increasingly used to measure
the effectiveness and costs in cost-effectiveness analysis (CEA). However, the …
the effectiveness and costs in cost-effectiveness analysis (CEA). However, the …
Real-world evidence: bridging gaps in evidence to guide payer decisions
MH Roberts, GT Ferguson - PharmacoEconomics-Open, 2021 - Springer
Randomized controlled trials (RCTs) are preferred by payers for health technology
assessments and coverage decisions. However, the inclusion of a highly selective patient …
assessments and coverage decisions. However, the inclusion of a highly selective patient …
Methods for economic evaluations of novel oral anticoagulants in patients with atrial fibrillation: a systematic review
Y Li, P Chen, X Wang, Q Peng, S Xu, A Ma… - Applied Health Economics …, 2024 - Springer
Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …
among the elderly population worldwide, with substantial economic and social burdens …
Impact of fall risk and direct oral anticoagulant treatment on quality-adjusted life-years in older adults with atrial fibrillation: a Markov decision analysis
W Wei, RS Rasu, JJ Hernández-Muñoz, RJ Flores… - Drugs & Aging, 2021 - Springer
Abstract Background and Objective The decision to initiate anticoagulation in older adults
with atrial fibrillation is complicated by the benefit of ischemic stroke prevention vs the risk of …
with atrial fibrillation is complicated by the benefit of ischemic stroke prevention vs the risk of …
The guideline-policy gap in direct-acting oral anticoagulants usage in atrial fibrillation: evidence, practice, and public policy considerations
D Wan, JS Healey, CS Simpson - Canadian Journal of Cardiology, 2018 - Elsevier
Atrial fibrillation has a high disease burden—both in prevalence and associated
consequences. Despite anticoagulation being an effective treatment in atrial fibrillation …
consequences. Despite anticoagulation being an effective treatment in atrial fibrillation …
Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France
K Bowrin, JB Briere, L Fauchier, C Coleman, A Millier… - PLoS …, 2020 - journals.plos.org
Objective The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …
Supplementary appendices
R Noviyani, S Youngkong, S Nathisuwan… - BMJ, 2022 - ebm.bmj.com
The relevant cost-effectiveness study reports economic terms in the currency units of each
country at a certain time unit, so that currency conversion is needed for the standardization …
country at a certain time unit, so that currency conversion is needed for the standardization …
Review of cost-effectiveness of antithrombotic alternatives in patients with atrial fibrillation
J Cruz, LO Barros, SSF Morais… - Revista da Associação …, 2021 - SciELO Brasil
A cerebrovascular accident is a pathological entity with the vascular impairment of sudden
onset, which leads to the lowering of the level of consciousness, differentiating it into …
onset, which leads to the lowering of the level of consciousness, differentiating it into …
[PDF][PDF] Farmeconomia. Health economics and therapeutic pathways 2017; 18 (1): 103-111
ABSTRACT BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20)
are indicated for the prevention of thromboembolic events in patients with Non-Valvular …
are indicated for the prevention of thromboembolic events in patients with Non-Valvular …